<DOC>
	<DOCNO>NCT01835548</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group , Phase 3 trial evaluate safety efficacy NT0102 treatment Attention Deficit Hyperactivity Disorder ( ADHD ) pediatric patient 6 12 year age .</brief_summary>
	<brief_title>NT0102 Treatment Children With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel group , Phase 3 trial evaluate safety efficacy NT0102 treatment Attention Deficit Hyperactivity Disorder ( ADHD ) pediatric patient 6 12 year age laboratory classroom study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Currently treat ADHD Other psychiatric diagnosis Significant cognitive impairment Chronic medical illness Structural cardiac defect Significant abnormal lab test Taking disallowed medication Positive drug test</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>